


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: SU et al.

Application Serial No.: 09/416,267

Filed: October 12, 1999

For: Human Cytokine Polypeptide



Group Art Unit: 1632

Examiner: To be assigned

Atty. Docket No.: PF270P1

**STATEMENT UNDER 37 C.F.R. §§1.821(e)-(f)**

Assistant Commissioner For Patents  
Washington, D.C. 20231


Sir:

Applicants hereby certify under 37 C.F.R. §§1.821(e)-(f) that the content of the paper form of the Sequence Listing submitted in the instant application, and the computer-readable form of the Substitute Sequence Listing submitted herewith, is the same.

Moreover, applicants hereby certify under 37 C.F.R. §§1.821(g) and 1.825(a) the Substitute Sequence Listing contains no new matter.

Respectfully submitted,

Dated: 1/4/00

  
Joseph J. Kenny (Reg. No. 43,710)  
Agent for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, Maryland 20850  
Telephone: (301) 610-5800

Enclosures  
MMW/JJK/lcc



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARK  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/416,267 10/12/99 SU

K PF270P1

0232/1105

HUMAN GENOME SCIENCES INC.  
9410 KEY WEST AVENUE  
ROCKVILLE MD 20850

NOT ASSIGNED



1632

DATE MAILED:

11/05/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file a sequence listing in compliance with 37 CFR 1.821 - 1.825 to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☐ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

*J. Wade*  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202